Dulaglutide
Brand: Trulicity
Antidiabetic
GLP-1 receptor agonist (once-weekly)
Pharmacokinetics
| Half-life | 5 days |
| Tmax | 48 h |
| Clearance Route | other |
| Active Metabolites | no |
| Notes | Long half-life (~5 days) supports once-weekly dosing; not CYP metabolized; mainly degraded to peptides/amino acids. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Nausea, vomiting, diarrhea, abdominal pain, decreased appetite
Contraindications:
Personal/family history of medullary thyroid carcinoma, MEN2
Precautions:
Pancreatitis risk; hypoglycemia mainly with insulin/sulfonylureas; may delay gastric emptying and affect absorption of oral drugs